Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respectively, a 7% Increase Compared to Both 2019 Periods; Company Reiterates Full-Year 2020 Total Revenue Guidance of $132 Million to $137 Million. Net Income for Third Quarter and First Nine Months of 2020 was $6.8 million and $15.5 million, Respectively, […]
Treatment with Kamada’s Investigational IgG Product Will Be Regulated by the Israeli Ministry of Health. Initial Order Sufficient to Treat 500 Patients. Positive Interim Safety and Symptoms Improvement Observed in Fully Enrolled Ongoing Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial of Company’s Hyperimmune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with Pneumonia. S. Clinical […]
Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement Kamada Projects Royalties from Takeda in the Range of $10 Million to $20 Million per Year from 2022 to 2040 Kamada Reiterates its Total Revenues Guidance […]
The Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial is Testing Kamada’s Hyper-immune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with Pneumonia Symptoms Improvement Observed in 11 of the 12 Patients within 24 to 48 Hours of Treatment; All 11 Patients Subsequently Discharged from Hospital within a Median of 4.5 Days from Treatment. IgG Product […]
The Study of KEDRAB® (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S. The Study Met its Primary Objective, Which Was to Confirm the Safety of KEDRAB in the Pediatric Population. Study Results Have Been Submitted to the U.S. FDA for Review and Potential […]
Click here for the recording of Kamada second quarter 2020 investor call. Second Quarter Revenues were $1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million, up 7% from 2019. Net Income for the Second Quarter and for the First Half of 2020 was $3.5 million and $8.7 million, Respectively, Compared […]
Study Participants are Hospitalized, Non-ventilated COVID-19 Patients with Pneumonia Encouraging Neutralization Activity Observed with Virus Neutralization Assay Pre-IND Meeting with U.S. FDA to be Conducted in Current Quarter, with U.S. Clinical Development Expected to Commence in Early 2021 Kamada Intends to Further Explore its IgG Product as a Potential Preventive Therapy for COVID-19 Disease in […]
Kamada Completed Manufacturing and Released the First Batch of its Plasma-Derived Immunoglobulin Product for Coronavirus Disease (COVID-19) and it is Available for Compassionate Use Treatment in Israel; Additional Production is On-Going Kamada Intends to Initiate a Phase 1/2 Clinical Study in Hospitalized COVID-19 Patients in Israel During the Third Quarter of 2020 Kamada and its […]
Total Revenues were $33.3 Million, an Increase of 24% Year-over-Year Net Income was $5.2 Million, an Increase of 6% Year-over-Year Company Reports Continued Progress of its Development Program of a Plasma-Derived Hyperimmune IgG Therapy for COVID-19; Product Availability for Clinical and Compassionate Use Treatment for COVID-19 patients in Israel is Expected by End of the […]
Rehovot, Israel, May 11, 2020 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets on Monday, May 18, 2020. Kamada management will host an investment community conference call on […]